Update on January bond calls

In January, I posted that it was looking reasonable to short Treasurys, long junk bonds (but a better entry price could be had), and probably avoid (but not short) higher grade corporates and munis in general. How has that done since my post on January 6th?
Using the ETF proxies: TLT (long bond): -13%, so [...]

Briefcase cleaning

Funny story. I was cleaning out my briefcase and came across three old stock reports that I wrote for an interview last year with a fund manager. I didn’t get the job due to my “inexperience, particularly with foreign stocks (which admittedly I didn’t have a lot of experience with). Anyway, the stocks were: Celanese [...]

Another day, another 10% swing

Gee, this volatility (http://finance.yahoo.com/echarts?s=%5EGSPC#symbol=%5EGSPC;range=1d) is getting to be almost boring. I don’t pretend to be a technician but it does appear that the market is trying to bottom out around 800-850 on the S&P.
I was fortunate enough to catch some high quality names closer to the low than the high today, and [...]

Investing in Biotech–The First Commandment

Let’s think about an industry where the companies have a product development time of 7-10 years, at a cost of a minimum of $100M (I’m not talking about the famous Tufts numbers here, I’m assuming you’re lucky and that one compound makes it through the clinic unscathed), and at the end of it all is [...]

The mysteries of biotechnology investing

Introducing a blog by an ex-stock analyst, ex-Motley Fool author on the ins&outs of biotech stock investing.  I aim to provide my philosophy on how to make money going both long and short (very important!) biotech stocks in the next few posts and then get on to actual stock picking…